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 Summary at a Glance 
 
Metformin is commonly used for diabetic patients and has recently been found to reduce 
airway inflammation in animal studies. We evaluated the association between metformin use 
and asthma exacerbation among patients with concurrent asthma and diabetes, and found that 
the risk of exacerbation was lower among metformin users than non-users.  
   
  




Background and objective 
Metformin is a first-line treatment for patients with diabetes. Recent animal studies 
indicated that metformin can reduce airway inflammation. However, it remains unclear 
whether the use of metformin can help patients maintain asthma control. The purpose of this 
study was to evaluate the association between the use of metformin and asthma-related 
outcomes, which include asthma-related hospitalization, asthma-related emergency room visits, 
and asthma exacerbation, among patients with concurrent asthma and diabetes. 
 
Methods 
We conducted an 11-year (2001-2011) retrospective cohort study using the Taiwan 
National Health Insurance Research Database. Patients with concurrent asthma and diabetes 
were included. The date of the first observed prescription of metformin was defined as the 
index date. For each metformin user, two matched metformin non-users of the same age and 
gender were randomly selected. Patients were followed for three years to measure the 
occurrence of asthma related outcomes. Multivariable logistic regression models were used to 
assess the association between metformin use and asthma-related outcomes. 
 
Results 
Of 1,332 patients with concurrent asthma and diabetes, 444 (33.3%) were metformin users. 
Compared to non-users, metformin users had a lower risk of asthma-related hospitalization 
(odds ratio (OR) = 0.21, 95% confidence interval (CI): 0.07-0.63) and asthma exacerbation 
(OR = 0.39, 95% CI: 0.19-0.79). 





The risk of asthma-related outcomes was lower for metformin users than non-users. 
Health care providers should consider metformin as a treatment strategy for patients with 
concurrent asthma and diabetes.  
 
Keywords: Asthma, claims data, diabetes, metformin, The National Health Insurance 
Research Database  
  
Short Title: Metformin and asthma outcome reduction  
 
 





ACOS Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome 
CCI Charlson Comorbidity Index 
COPD Chronic Obstructive Pulmonary Disease 
DPP-4 Dipeptidyl Peptidase 4 
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ICD-9-CM International Classification Of Diseases, 9th Revision, Clinical 
Modification 
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LABA Long-Acting-Β-Agonist 
LHID Longitudinal Health Insurance Database 
NHI National Health Insurance 
NHIRD National Health Insurance Research Database 
NHRI National Health Research Institute 
OR Odds Ratio 
PCOS Polycystic Ovarian Syndrome 
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  Introduction 
 
Asthma, a chronic disease involving inflammation in the small airways of the lungs, is a 
prevalent disease with considerable burden worldwide.1 Asthma affects more than 300 million 
people around the world.2 In the United States, an estimated 25.9 million people had asthma in 
2011.3 In Taiwan, asthma affects about 12% of the population.4 The mean cost of 
hospitalizations for patients with asthma in Taiwan is 2.7-times higher than for patients without 
asthma.5, 6 
Asthma is treatable, even though it remains a lifelong disease. Medications for treating 
asthma are grouped in two major classes: controller and reliever medications.7 Controller 
medications suppress inflammation or provide long-acting bronchodilation. Reliever 
medications have quick-onset bronchodilating effects and are used to treat acute asthma 
symptoms. Even though asthma is treatable, poor asthma control has often been reported in 
clinics.8, 9 For example, Carlton et al. conducted a survey of 60,000 patients in multiple 
primary care practice sites and reported that 74% of patients reported a lack of asthma 
control.10 
Diabetes is a common comorbid condition among adult patients with asthma. For example, 
previous population based studies reported that the range of the prevalence of comorbid 
diabetes was from 5 to 16%.11, 12 Compared to patients without diabetes, diabetics are also at 
increased risk for other respiratory diseases such as asthma, chronic obstructive pulmonary 
disease, pulmonary fibrosis, and pneumonia.13 Furthermore, studies also showed that patients 
with concurrent asthma and diabetes had poorer glycemic control 14, quality-adjusted life 
expectancy15 and higher risk of pneumococcal disease16 when compared with patients who 
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only have asthma or diabetes. 
Recent in-vitro and in-vivo studies showed that the anti-inflammatory effect of metformin 
can reduce airway inflammation.17, 18 The plausible mechanism of anti-inflammatory effect of 
metformin on the airway is believe to be mediated through metformin activated 5' adenosine 
monophosphate-activated protein kinase (AMPK).18 Activation of AMPK inhibits 
inflammatory processes associated with conditions such as colitis, cystic fibrosis, and 
autoimmune encephalomyelitis.19-22 AMPK activity may also decrease oxidative stress, through 
the regulation of the cellular proliferation and protein synthesis and its effects on nicotinamide 
adenine dinucleotide phosphate-oxidases.23 For example, Calixto et al. conducted a study 
among obese mice model fed with a high fat-diet, and found that metformin attenuated the 
exacerbation of the allergic eosinophilic inflammation.17 Another activity of metformin 
includes inhibition of tumor necrosis factor-α-induced inflammatory signaling and nuclear 
factor-kB-mediated inducible nitric oxide synthase expression.18  
Given metformin is recommended as a first-line treatment for patients with diabetes,24 it 
may become a better treatment option for better asthma control among patients with concurrent 
asthma and diabetes. However, it is unclear whether the use of metformin can help patients 
maintain better asthma control. Therefore, the purpose of this study was to evaluate the 
association between the use of metformin and asthma-related outcomes among patients with 
concurrent asthma and diabetes. We hypothesized that the risk of asthma-related adverse 
outcomes would be lower in metformin users than in non-users. 
  





The National Health Insurance Research Database (NHIRD) in Taiwan was used to 
conduct this study. In 1995, the Taiwanese government launched its National Health Insurance 
(NHI) program that covered 23 million citizens, which accounted for 98% of the population in 
Taiwan.25-27 The health information recorded in the NHI program was used to build the NHIRD 
which is maintained by the Bureau of National Health Insurance of Taiwan and National 
Health Research Institute (NHRI).27 The NHIRD is a de-identified, administrative claims 
database that contains beneficiaries’ demographics, diagnosis, inpatient and outpatient 
procedures, prescription drugs, and enrollment information. 
We used the 2005 Longitudinal Health Insurance Database (LHID 2005) which is a 
sample containing one million Taiwanese beneficiaries in 2005 randomly selected from the 
NHIRD to conduct this study.27 The overall length of the data in our study was 11 years from 
January 1, 2001 to December 31, 2011. 
Study population and design 
A retrospective cohort study design was used to conduct this study. Figure 1 describes the 
overall study design. Adult patients aged ≥18 years with concurrent asthma and diabetes were 
included in our study population. The International Classification of Diseases, 9th Revision, 
Clinical Modification (ICD-9-CM) codes were used to identify patients. To be included in the 
population, patients needed to have had at least one inpatient or two outpatient diagnoses of 
asthma (ICD-9-CM: 493.x) and diabetes (ICD-9-CM: 250.x) during the enrollment period (i.e., 
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January 1, 2002 to December 31, 2008). In addition to the disease diagnosis, patients were 
included if they had at least one prescription for asthma and diabetes medication during the 
enrollment period. The index date of the metformin users was defined as the date of the first 
observed prescription record of metformin during the enrollment period. For each metformin 
user, two matched metformin non-users of the same age and gender were selected, and they 
were assigned the same index date as the matched metformin users. To ensure the patients 
included in our study were with concurrent asthma and diabetes, we further restricted that the 
date of the asthma and diabetes diagnosis must be earlier than the index date. Patients were 
followed for three years (i.e., the follow-up period) from the index date to measure 
asthma-related outcomes. Figure 2 describes the process of identifying the study population. 
We excluded patients who had a metformin prescription within one year before the index 
date (i.e., the pre-index period). We furthered excluded patients if they had been diagnosed 
with chronic obstructive pulmonary disease (COPD) (ICD-9CM codes 491.xx, 492.xx, or 
496.xx), any respiratory tract cancer (ICD-9-CM codes 161, 161.x, 162, 163, 163.x, 231, 
231.x), or bronchiectasis (ICD-9-CM code 494.xx) during the pre-index period.28-30 Patients 
were also excluded if they had an asthma-related hospitalization or emergency room visit 
during the pre-index period. Finally, patients with invalid or missing information of age, gender, 
diagnosis codes, medication prescriptions, and enrollment records were excluded. 
Dependent variables 
Three dependent variables were measured in our study: asthma-related hospitalization, 
asthma-related emergency room visits, and the risk of asthma exacerbation.30-32 We only used 
the primary diagnosis of asthma to identify asthma related outcomes. The asthma-related 
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hospitalization was defined as a patient with an asthma-related hospital admission during the 
follow-up period. The asthma-related emergency room visit was defined as a patient having an 
asthma-related emergency room visit during the follow-up period. Asthma exacerbation was 
defined as a patient who used a systemic corticosteroid plus had an asthma-related hospital 
admission or a systemic corticosteroid plus had an emergency room visit during the follow-up 
period.32, 33 To ensure the validity of the outcome, we further required that the systemic 
corticosteroid use and hospitalization (or emergency room visit) for asthma occurred for the 
same event.   
Covariates 
All covariates were measured during the pre-index period. They were age, gender, 
geographic region, the Charlson Comorbidity Index (CCI),34, 35 duration of asthma, use of 
asthmatic medications, use of diabetic medications, all-cause hospitalization, and all-cause 
emergency room visits. We created a covariate called cardiovascular and metformin-related 
discontinue diseases, which includes cardiovascular diseases, dyslipidemia, metabolic 
syndrome end stage renal disease, heart failure, or chronic liver disease. We adjusted the 
variable in addition to CCI to better control the confounding effect from comorbidity. 
Geographic areas in Taiwan were grouped into six regions: northern, northwestern, central, 
southwestern, southern, eastern, and other. The use of the asthmatic medications was defined 
as the documentation of patients having at least one prescription for any of the following 
asthma medications in the pre-index period: inhaled corticosteroids (ICSs), 
long-acting-β-agonists (LABAs), leukotriene modifiers, methyl-xanthine, short-acting 
β-agonists (SABAs), Cromones, anti-immunoglobulin E (IgE), and systemic corticosteroids. 
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The diabetic medication use was defined as patients having at least one prescription for the 
following diabetes medications during the pre-index period: sulfonylurea, meglitinide, 
thiazolidinedione, α-glucosidase inhibitors, inhibitors of dipeptidyl peptidase 4 (DPP-4), 
glucagon-like peptide (GLP)-1 agonists, and insulin. Each drug name in the category was listed 
in the appendix (Appendix 1). 
Statistical analysis 
Descriptive statistics were used to describe patient characteristics of the overall study 
population, metformin users, and metformin non-users. The Student's t-test and Chi-square test 
were used to compare differences in means of continuous variables and percentage differences 
of categorical variables between metformin users and non-users. 
Multivariable logistic regression models were used to estimate adjusted odds ratios (ORs) 
between the use of metformin and the three dependent variables in our study. In the 
multivariable regression models, we evaluated the association between asthma-related 
outcomes and metformin use after adjusting the variables listed in the above Covariates section 
including age, gender, region, the CCI, all-cause-related hospitalization, all-cause-related 
emergency room visit, duration of asthma, medications for asthma, and medications for 
diabetes.  
The asthma exacerbation measurement in our main analysis was patients using systemic 
corticosteroids plus asthma related hospitalization or patients using systemic corticosteroids 
plus asthma related ER visit. In addition to the main analysis, we further conducted a 
sensitivity analysis to define the asthma exacerbation as a composite outcome of the 
occurrence of systemic corticosteroids use, asthma related hospitalization, or asthma related 




SAS® Proprietary Software, Release 9.3 (SAS Institute, Cary, NC) was used for data 
management and statistical analyses. A p value with two-tailed significance level was set to 
0.05. This study was reviewed and approved by the Taipei Medical University Joint 
Institutional Review Board. 
  





Table 1 shows characteristics of the study population. The mean age was 64 years, and 
more than half were females (60.4%). The mean score of the CCI was 1.3. About 23.7% and 
28.6% had a hospital admission and emergency room visit, respectively, during the one year 
pre-index period. About 14.2% took a LABA, 26.1% took a short-acting β-agonist, and 20.4% 
took a systemic corticosteroid. More than one-third (38.5%) of the study population took 
sulfonylurea during the pre-index period. 
Table 2 presents the comparison of the patient characteristics between metformin users 
and non-users. Metformin users took more short-acting β2-agonist (30.2% vs. 24.1%, p < 0.05), 
and methyl-xanthine (42.8% vs. 32.8%, p < 0.01). The use rate of insulin was lower among 
metformin users (6.1% vs. 13.5%, p < 0.01). Metformin users had fewer asthma-related 
hospital admissions (0.9% vs. 3.3%, p < 0.01) than metformin non-users during the follow-up 
period. 
Table 3 shows the results of the adjusted multivariable logistic regression models. Results 
showed that metformin users were less likely to have asthma-related adverse outcomes. 
Compared to metformin non-users, metformin users had a lower risk of asthma related 
hospitalization (OR = 0.21, 95% CI: 0.07-0.63) and asthma exacerbation (OR = 0.39, 95% CI: 
0.19-0.79), but not emergency room visits for asthma (OR=0.62, 95%CI 0.26-1.44)  
Results from the sensitivity analysis showed that the risk of asthma exacerbation was not 
significantly different between metformin users and non-users (OR = 0.68, 95% CI: 0.45-1.02).   





In this retrospective cohort study, we found a significant association between metformin 
use and asthma-related outcomes among patients with concurrent asthma and diabetes. 
Metformin users were less likely to have an asthma-related hospitalization and an asthma 
exacerbation than metformin non-users. Our findings confirmed that the anti-inflammatory 
effect of metformin may be associated with a reduced risk of airway inflammation, which was 
reported in previous animal studies.17, 18 
Although the plausible mechanism remains unclear, previous in-vitro and in-vivo studies 
showed that metformin could have anti-inflammatory effect.17, 18 Through the activation of the 
AMPK, metformin attenuates the exacerbation of the allergic eosinophilic inflammation, which 
reduces the airway inflammatory.18 The activation of the AMPK could also inhibit the 
inflammatory process in several other diseases such as colitis,20 cystic fibrosis,21 autoimmune 
encephalomyelitis22 and LPS-induced lung inflammation.36 Therefore, a lower risk of asthma 
exacerbation among metformin users that we observed in the study could result from this 
anti-inflammatory effect.  
This study has several strengths. To our knowledge, this is the first study to evaluate the 
association between metformin use and asthma-related outcomes in a large, population-based 
cohort. Then, we used both the disease diagnoses and medication records, which can prevent 
the misclassification that was commonly reported in studies using administrative claims data, 
to ensure the accuracy and validity of identifying our study population.37 Furthermore, we 
adopted the new user design38 to prevent the immortal bias that was commonly reported in the 
observational studies.39, 40 Furthermore, we identified asthma-related medication use which 
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included the use of ICS, LABA, and short-acting β-agonists, and adjusted the medication use in 
the regression model. The model allowed us to obtain a more comprehensive finding because 
the management of asthma-related medication was highly associated with the asthma outcomes. 
Finally, we also adjusted for diabetic patients’ medication use including insulin in our 
regression analysis. Including diabetic medication use can potentially serve as a proxy of the 
severity of the diabetic condition. The adjustment ensured that we obtained comprehensive and 
objective findings. 
Moreover, we used asthma exacerbation because it is a more comprehensive and clinically 
meaningful outcome. We found that the risk of asthma exacerbation was lower among 
metformin users than non-users. Metformin is a first-line medication treatment that is widely 
used for patients with diabetes. Physicians may consider prescribing metformin or adding 
metformin to current diabetic medicines as a treatment strategy for patients with concurrent 
asthma and diabetes. 
Previous studies indicated that metformin can reduce the risk of cancer, HIV 
lipodystrophy syndrome, polycystic ovarian syndrome (PCOS), and several chronic 
inflammatory diseases through its anti-inflammatory effect.41, 42 The association between 
metformin use and the reduced risk of the asthma exacerbation that we found in this study 
needs further investigation. Several ongoing randomized control trials may provide more 
evidence to support our findings.43, 44 
There are several limitations to this study. First, several risk factors, which can impact 
asthma control including obesity, allergens, infections, occupational sensitizers, smoking, air 
pollution, and dietary habits, were not available in the administration claims data.1 Second, the 
NHIRD does not have information regarding the socioeconomic status such as education, 
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family income, race/ethnicity, marital status, etc., which are confounders for asthma 
exacerbation. The residual confounding effect can still exist. In addition, the NHRID did not 
provide the laboratory data or other clinical measures such as body mass index (BMI), which 
were potential confounders in this study. Third, symptom overlaps could exist between patients 
with chronic COPD and asthma.45, 46 We potentially eliminated patients with severe asthma 
when we excluded patients with COPD. This exclusion criterion would have lowered the 
generalizability and validity of our study. Fourth, bias created from confounding by indication 
may exist because the number of comorbid conditions and medication use were higher for 
metformin users than non-users. Fifth, actual medication adherence in the study population was 
unknown because a record of prescriptions filled might not mean a prescription taken by the 
patient. Finally, asthma is a heterogeneous disease,47 and information regarding the phenotypes 
or severity of asthma was not available in the claims data. 
In summary, metformin use is potentially associated with improvements in asthma control 
among patients with concurrent asthma and diabetes. From a clinical perspective, metformin 
can become a priority selection among patients with diabetes and asthma. Future studies can 
continue to investigate the underlying anti-inflammatory mechanism of metformin, and clinical 
trials are necessary to further confirm the effect of metformin on asthma control.
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Table 1 Baseline characteristics of the study population* 
  Overall population 
 
(N=1,332) 
Characteristics Estimated population Percentage 
Age (mean, SD)a 64  10.1  
Agea 
  
18 - 39 24   1.8% 
40 - 59 402  30.2% 
60 - 79 906  68.0% 
Gender  
  
Female 804  60.4% 
Male 528  39.6% 
Regiona 
  
Northern 342  25.7% 
Northwest 202  15.2% 
Central 247  18.5% 
Southwestern 204  15.3% 
Southern 213  16.0% 
Eastern and other 124   9.3% 
Charlson-Comorbidity-Index (mean, SD)b               1.3  1.8  
Duration of asthma (mean of months, SD)c               41.9  21.2  




Yes 316  23.7% 
Emergency room visit 
  
Yes 381  28.6% 
Cardiovascular diseased 
  
Yes 76   5.7% 
Metformin-related discontinue diseasese 
  
Yes 90   6.7% 




Yes 93   7.0% 





Yes 189  14.2% 
Short-acting β2-agonist 
  
Yes 348  26.1% 
Leukotriene modifiers 
  
Yes 20   1.5% 
Methyl-xanthine 
  
Yes 481  36.1% 
Systemic corticosteroid 
  
Yes 272  20.4% 
Anticholinergics 
  
Yes 49   3.7% 




Yes 513  38.5% 
Meglitinide 
  
Yes 72   5.4% 
Thiazolidinedione 
  
Yes 77   5.8% 
α-glucosidase inhibitor 
  
Yes 111   8.3% 
Insulin 
  
Yes 147  11.0% 




Yes 33   2.5% 
Emergency room visit 
  
Yes 30   2.3% 
Exacerbation 
  
Yes 133  10.0% 
a. Calculated on the index date 
b. Calculated during the pre-index period 
c. Duration between the date of first diagnosis with asthma and the index date in the enrollment 
period 
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d. Including cardiovascular disease, dyslipidemia or metabolic syndrome 
e. Including end stage renal disease, heart failure or chronic liver disease 
f. Calculated during the follow-up time 
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Table 2 Comparisons of patient characteristics between metformin users and non-users* 











Age (mean, SD)a 64  10.1  64  10.1  0.98  
Agea 
    
1.00  
18 - 39 8   1.8% 16   1.8% 
 
40 - 59 134  30.2% 268  30.2% 
 
60 - 79 302  68.0% 604  68.0% 
 
Gender  
    
1.00  
Female 268  60.4% 536  60.4% 
 
Male 176  39.6% 352  39.6% 
 
Regiona 
    
0.05  
Northern 97  21.9% 245  27.6% 
 
Northwest 82  18.0% 120  13.5% 
 
Central 76  17.1% 171  19.3% 
 
Southwestern 69  15.5% 135  15.2% 
 
Southern 72  16.2% 141  15.9% 
 
Eastern and other 48  10.8% 76   8.6% 
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Charlson-Comorbidity-Index (mean, SD)b 1.3  10.81  1.4  1.86  0.46  
Duration of asthma (mean of months, SD)c 39.7  21.95  43.0  20.73  <0.01* 
All cause eventsb 
     
Hospital admission 
    
0.74  
Yes 103  23.2% 213  24.0% 
 
Emergency room visit 
    
0.69  
Yes 124  27.9% 257  28.9% 
 
Cardiovascular diseased 
    
0.15  
Yes 31   7.0% 45   5.1% 
 
Metformin-related discontinue diseasese 
    
0.81  
Yes 31   7.0% 59   6.6% 
 
Inhaled corticosteroid 
    
0.11  
Yes 38   8.6% 55   6.2% 
 
Long-acting β-agonist 
    
0.86  
Yes 64  14.4% 125  14.1% 
 
Short-acting β2-agonist 
    
0.02  
Yes 134  30.2% 214  24.1% 
 
Leukotriene modifiers 
    
0.75  
Yes 6   1.4% 14   1.6% 
 
Methyl-xanthine 
    
<0.01* 
Yes 190  42.8% 291  32.8% 
 




    
0.02  
Yes 107  24.1% 165  18.6% 
 
Anticholinergics 
    
0.09  
Yes 11   2.5% 38   4.3% 
 
Medication for diabetesb 
     
Sulfonylurea 
    
0.12  
Yes 184  41.4% 329  37.1% 
 
Meglitinide 
    
<0.01* 
Yes 15   3.4% 57   6.4% 
 
Thiazolidinedione 
    
0.16  
Yes 20   4.5% 57   6.4% 
 
α-glucosidase inhibitor 
    
0.67  
Yes 39   8.8% 72   8.1% 
 
Insulin 
    
<0.01* 
Yes 27   6.1% 120  13.5% 
 
Asthma-related outcome variablesf 
     
Hospital admission 
    
<0.01* 
Yes 4   0.9% 29   3.3% 
 
Emergency room visit 
    
0.43  
Yes 8   1.8% 22   2.5% 
 
Exacerbation 
    
0.02  
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Yes 10   2.3% 44   5.0% 
 
*Difference of the covariates between metformin users and non-metformin users, using student-t test and 
chi-square test. P-value with two-tailed significance level was set to 0.05  
a. Calculated on the index date 
b. Calculated during the pre-index period 
c. Duration between the date of first diagnosis with asthma and the index date in the enrollment period 
d. Including cardiovascular disease, dyslipidemia or metabolic syndrome 
e. Including end stage renal disease, heart failure or chronic liver disease 
f. Calculated during the follow-up time 
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Table 3: The associations between metformin use and asthma outcomes (hospitalization, emergency room visit and exacerbation): 
results from multivariable logistic regression modelsa 
 
Asthma hospitalization Asthma emergency room visit Asthma exacerbation 
 
Adjusted model Adjusted model Adjusted model 
Variable Odds ratio (95% CI)  Odds ratio (95% CI)  Odds ratio (95% CI)  
Use of metformin 
      
Yes 0.21  ( 0.07 - 0.63 ) 0.62  ( 0.26 - 1.44 ) 0.39  ( 0.19 - 0.79 ) 
No Reference Reference Reference Reference Reference Reference 
Age 1.02  ( 0.99 - 1.06 ) 0.98  ( 0.94 - 1.01 ) 1.01  ( 0.98 - 1.03 ) 
Genderb 
      
Female 1.91  ( 0.83- 4.37 ) 0.96  ( 0.45 - 2.04 ) 1.46  ( 0.79 - 2.69 ) 
Regionb 
      
Northwest 3.80  ( 1.23 -11.73 ) 2.08  ( 0.72 - 5.97 ) 1.83  ( 0.81 - 4.11 ) 
Central 1.58  ( 0.46 - 5.38 ) 1.12  ( 0.37 - 3.46 ) 1.07  ( 0.45 - 2.51 ) 
Southwestern 1.56  ( 0.44 - 5.59 ) 0.67  ( 0.17 - 2.67 ) 0.98  ( 0.40 - 2.45 ) 
Southern 1.48  ( 0.41 - 5.37 ) 0.74  ( 0.21 - 2.69 ) 0.79  ( 0.30 - 2.07 ) 
Eastern and other 0.88  ( 0.16 - 4.81 ) 0.66  ( 0.13 - 3.29 ) 0.55  ( 0.15 - 2.03 ) 
Charlson Comorbidity Index 0.86  ( 0.66 - 1.13 ) 1.01  ( 0.81 - 1.27 ) 0.91  ( 0.75 - 1.11 ) 
Duration of asthmac 1.00  ( 0.99 - 1.02 ) 1.00  ( 0.98 - 1.02 ) 1.00  ( 0.99 - 1.01 ) 
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Cardiovascular and metformin-related 
discontinue diseaseb,d       
Yes 0.27  ( 0.03 - 2.16 ) 1.30  ( 0.41 - 4.18 ) 1.06  ( 0.41 - 2.74 ) 
Medication for asthma 
      
Inhaled corticosteroidb 
      
Yes 1.89  ( 0.64 - 5.60 ) 3.74  ( 1.34 - 10.4 ) 1.22  ( 0.49 - 3.05 ) 
Long-acting β-agonistb 
      
Yes 2.21  ( 0.90 - 5.41 ) 0.60  ( 0.20 - 1.80 ) 1.91  ( 0.95 - 3.85 ) 
Short-acting β2-agonistb 
      
Yes 1.87  ( 0.84 - 4.19 ) 1.44  ( 0.62 - 3.32 ) 1.77  ( 0.95 - 3.28 ) 
Systemic corticosteroidb 
      
Yes 2.21  ( 0.87 - 4.72 ) 1.86  ( 0.79 - 4.37 ) 1.64  ( 0.85 - 3.17 ) 
Other medicationb,e 
      
Yes 1.05  ( 0.44 - 2.52 ) 1.10  ( 0.46 - 2.65 ) 1.26  ( 0.66 - 2.41 ) 
Medications for diabetesb,f 
      
Yes 0.85  ( 0.41 - 1.77 ) 1.28  ( 0.6 - 2.77 ) 1.13  ( 0.64 - 2.00 ) 
a. Adjusted variables including age, gender, region, Charlson Comorbidity Index, duration of asthma, medications for asthma, medication for 
diabetes  
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b. Reference groups: gender (male), region (northern), cardiovascular and metformin-related discontinue disease (No), inhaled corticosteroid (No), 
long-acting β-agonist (No), short-acting β2-agonist (No), systemic corticosteroid (No), other medications (No), and medications for diabetes (No)     
c. Duration between the date of first diagnosis with asthma and the index date in the enrollment period 
d. Including cardiovascular disease, dyslipidemia, metabolic syndrome, end stage renal disease, heart failure or chronic liver disease 
e. Other medications including leukotriene modifier, methyl-xanthine and anti-cholinergic agent 
f. Medication for diabetes including sulfonylurea, meglitinide, thiazolidinedione, α-glucosidase inhibitor and insulin 
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 Figure legends 
  
Figure 1 Description of the study design 
 
Figure 2 Flow chart: the identification process of the study population 
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